Kristina Rosqvist

Dr. Kristina Rosqvist

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2016 in Acta Neurologica Scandinavica
Verified
Journal Article
Closed access
PDF file
KRKristina Rosqvist
Kristina Rosqvist
PHP. Hagell
P. Hagell
POP. Odin
P. Odin
HEH. Ekström
H. Ekström
Susanne IwarssonSusanne Iwarsson
Susanne Iwarsson
MNM. H. Nilsson
M. H. Nilsson

14 January 2022 in Brain Sciences
Verified
Journal Article
Open access
PDF file
KRKristina Rosqvist
Kristina Rosqvist
ASAnette-Eleonore Schrag
Anette-Eleonore Schrag
POPer Odin
Per Odin
TCthe CLaSP Consortium
the CLaSP Consortium
Parkinson’s disease (PD) is a chronic, progressive, neurodegenerative disease involving both motor and non-motor symptoms (NMS). In the late stage of the disease, Hoehn and Yahr (HY) stages IV-V, the symptomatology is often severe and patients become increasingly dependent on help in their daily life, resulting in an increased burden for the informal caregivers. To assess the implications of the caregiver burden, caregiver quality of life (QoL) was assessed in 74 informal caregivers to patients in late stage PD, by the Alzheimer’s Patient Partners Life Impact Questionnaire (APPLIQue), which has been found useful also in PD. The majority of caregivers were the spouse/partner. Individual items provided information on which aspects of caregiver burden were the most common, i.e., items: “feel guilty if not there” (71% affirmed), “situation wears me down” (65% affirmed) and “always on my mind” (61% affirmed). In simple linear regression analyses, female patient gender (p = 0.007), better cognition (p = 0.004), lower NMS burden (p = 0.012) and not being the partner (p = 0.022) were associated with better caregiver QoL. Multivariable linear regression analyses identified better cognition (p = 0.004) and female patient gender (p = 0.035) as independently associated with better informal caregiver QoL. Identifying and treating NMS as well as recognizing and alleviating caregiver burden seem essential to enhance QoL for both patients and caregivers in late stage PD.

17 February 2018 in Journal of Parkinson’s Disease
Verified
Journal Article
Closed access
PDF file
KRKristina Rosqvist
Kristina Rosqvist
MHMalcolm Horne
Malcolm Horne
PHPeter Hagell
Peter Hagell
SISusanne Iwarsson
Susanne Iwarsson
MNMaria H. Nilsson
Maria H. Nilsson
POPer Odin
Per Odin
Background: It is unclear to which degree Levodopa (L-dopa) remains effective also in the late stage of Parkinson’s disease (PD) and to which degree motor fluctuations and dyskinesias remain a problem. Objective: To assess responsiveness of motor symptomatology to L-dopa in a group of patients with late stage PD. Moreover, to investigate the extent to which motor fluctuations and dyskinesias occur. Methods: Thirty PD patients in Hoehn and Yahr (HY) stages IV and V in “on” were included. L-dopa responsiveness was assessed with a standardized L-dopa test in the defined “off” and defined “on” states. Motor function was assessed by the Unified PD Rating Scale (UPDRS) III and timed tests. Motor fluctuations and dyskinesias were assessed by the UPDRS IV. The participants were further monitored for 10 days with a mobile movement-analyses-system, the Parkinson’s Kinetigraph (PKG). The median (q1–q3) L-dopa equivalent daily dose (LEDD) was 799 (536–973) mg. Results: The UPDRS III score improved with ≥15% in 15 (50%) and with ≥30% in six (20%) participants during the L-dopa test. The median (q1–q3) UPDRS III score in “off” was 46 (37–53) and in “on” 36 (28–46). Twenty-one (70%) of the participants reported either predictable or unpredictable “off” fluctuations (items 36–37). The prevalence of dyskinesias (item 32, duration of dyskinesias ≥1) was 47%. The PKG indicated that dyskinesias primarily were mild and that a majority had a pronounced “off” symptomatology, spending a large proportion of the day either asleep or very inactive. Conclusions: Half of a group of patients with late stage PD had an L-dopa response of ≥15% on the UPDRS III. According to the UPDRS IV, a majority of the patients had motor fluctuations and about half had dyskinesias, although the PKG results suggested that these were not very severe.

11 March 2021 in Movement Disorders Clinical Practice
Verified
Journal Article
Open access
PDF file
KRKristina Rosqvist
Kristina Rosqvist
POPer Odin
Per Odin
SLStefan Lorenzl
Stefan Lorenzl
WMWassilios Meissner
Wassilios Meissner
BBBas R. Bloem
Bas R. Bloem
TCthe Care of Late Stage Parkinsonism (CLaSP) Consortium
the Care of Late Stage Parkinsonism (CLaSP) Consortium
Background: There is limited knowledge on health‐related quality of life (HRQoL) in late‐stage Parkinson's disease (PD).Objective: To assess factors associated with HRQoL in patients with late‐stage PD, with a focus on health care provision.Methods: The Care of Late Stage Parkinsonism (CLaSP) project is the largest study on late‐stage PD to date. The current study analyzed data of 401 patients from 6 European countries in whom HRQoL was assessed with the 8‐item PD Questionnaire in patients without dementia. Factors potentially associated with HRQoL were assessed and examined in linear regression analyses.Results: Better HRQoL was associated with living at home, greater independence in activities of daily living (Schwab and England Scale), less severe disease (Hoehn and Yahr stage), better motor function (Unified PD Rating Scale Part III), and lower non‐motor symptoms burden (Non‐Motor Symptoms Scale [NMSS]) across all NMSS domains. Having a PDspecialist as physician for PD, contact with a PDnurse, and no hospital admission during the past 3 months were associated with better HRQoL, but having seen a physiotherapist or occupational therapist was associated with worse HRQoL.Conclusions: The results emphasize the importance of optimizing treatment for motor and multiple non‐motor symptoms to improve HRQoL in patients with late‐stage PD. PD‐specific health care resources, particularly PDnurses, are likely important in addressing issues to improve HRQoL in this population. Worse HRQoL in those who had recently seen a physiotherapist or occupational therapist may reflect referral based on factors not measured in this study.

23 October 2025 in Movement Disorders
Verified
Journal Article
Open access
VLValentina Leta
Valentina Leta
PZPavlos Zinzalias
Pavlos Zinzalias
LBLucia Batzu
Lucia Batzu
GMGargi Mandal
Gargi Mandal
JSJuliet Staunton
Juliet Staunton
Kallol (K) Chaudhuri also Ray-ChaudhuriKallol (K) Chaudhuri also Ray-Chaudhuri
Kallol (K) Chaudhuri also Ray-Chaudhuri
Background: Gut dysbiosis and gut‐brain‐axis involvement in people with Parkinson's disease ( PwP ) support the use of gut‐microbiota‐modulating interventions. Probiotics may help manage constipation in PwP ; however, mechanisms underpinning additional beneficial properties are unknown. Objective: The aim was evaluating the effects of a probiotic ( Lacticaseibacillus rhamnosus, Lactobacillus acidophilus, Lactiplantibacillus plantarum and Enterococcus faecium) on gut microbiota, inflammation, motor and non‐motor symptoms (NMS) in PwP and constipation. Methods: In this multicenter, randomized, double‐blind, placebo‐controlled trial (NCT05146921), PwP and constipation were randomized (1:1) to receive either the probiotic (4.08 × 10 8 CFU/mL) or placebo orally (70 mL/day) for 12 weeks. The primary endpoint was the differential abundance of gut microbiota taxa between baseline and end‐of‐treatment in the active versus placebo group. Secondary/exploratory endpoints included changes in inflammatory cytokines plasma levels, short‐chain fatty acids (SCFAs) plasma and fecal levels, motor and NMS outcomes after 12 weeks. A per‐protocol analysis was performed. Results: Between July 17, 2019 and February 6, 2022, 74 participants were randomized. Data from 35 (probiotic) and 33 (placebo) participants were analyzed. Enrichments of bacteria with beneficial health‐related properties ( Odoribacteraceae , Enterococcaceae , and Blautia faecicola ) were observed in the active group compared to placebo ( P ≤ 0.05). Proinflammatory cytokine TNF‐α plasma levels decreased with probiotic treatment and increased with placebo ( P < 0.05). No changes in SCFAs levels were observed. Reductions in time‐to‐ on and NMS scale scores ( P < 0.05) were observed only in the active group. Conclusions: This probiotic was effective in beneficially enriching the gut microbiota with potential to reduce systemic inflammation, shortening time‐to‐ on following levodopa administration, and alleviating NMS burden in PwP experiencing constipation. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

5 June 2018 in Journal of Parkinson’s Disease
Verified
Journal Article
Closed access
PDF file
KRKristina Rosqvist
Kristina Rosqvist
POPer Odin
Per Odin
PHPeter Hagell
Peter Hagell
SISusanne Iwarsson
Susanne Iwarsson
MNMaria H. Nilsson
Maria H. Nilsson
ASAlexander Storch
Alexander Storch
Background: Non-motor symptoms (NMS) are common in late stage Parkinson’s disease (PD), as the frequency and severity of most of these symptoms increase with advancing disease. Objective: To assess effect of dopaminergic therapy on NMS in late stage PD and to investigate relationships between dopaminergic effect on NMS and on motor function. Method: Thirty PD patients in Hoehn and Yahr (HY) stages IV and V in “on” were included. Dopaminergic effect on non-motor symptomatology was assessed by the modified version of the Non-Motor Symptoms Scale (NMSS) in the “off” and the “on” state during a standardized L-dopa test, in parallel also assessing motor function. Results: NMS were common and many of the symptoms occurred in >80% of the individuals. The highest NMSS scores were seen within the NMSS domains 3: mood/apathy and 7: urinary in both the “off” and the “on” state. There was a statistically significant ( p < 0.001) improvement in the modified NMSS total score (median) from 79 in “off” to 64 in “on”. There were statistically significant differences between the “off” and the “on” state for domains 2: sleep/fatigue, 3: mood/apathy, 5: attention/memory, 6: gastrointestinal and 7: urinary. The differences in the NMSS score between the “off” and the “on” state were in general larger for motor responders than for motor non-responders. In motor non-responders, differences of the NMSS score between the “off” and the “on” state were found for the total score, domain 3: mood/apathy and its item 11-flat moods. Conclusion: There is an effect of dopaminergic medication on NMS in late stage PD, to some extent also for those with a non-significant response on motor function during L-dopa test. It is therefore of importance to optimize dopaminergic therapy in order to give the most effective symptomatic treatment possible.